ANEB
Anebulo Pharmaceuticals Inc
$
2.400
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.450
Open
2.380
VWAP
2.39
Vol
41.06K
Mkt Cap
98.19M
Low
2.340
Amount
98.17K
EV/EBITDA(TTM)
--
Total Shares
25.93M
EV
84.50M
EV/OCF(TTM)
--
P/S(TTM)
--
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
Show More
2 Analyst Rating
25.00% Upside
Wall Street analysts forecast ANEB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANEB is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
25.00% Upside
Current: 2.400
Low
3.00
Averages
3.00
High
3.00
25.00% Upside
Current: 2.400
Low
3.00
Averages
3.00
High
3.00
Maxim
Michael Okunewitch
Buy
to
Hold
downgrade
2025-07-23
Reason
Maxim
Michael Okunewitch
Price Target
2025-07-23
downgrade
Buy
to
Hold
Reason
Maxim analyst Michael Okunewitch downgraded Anebulo Pharmaceuticals to Hold from Buy.
Maxim
Buy
downgrade
$6 -> $3
2025-05-15
Reason
Maxim
Price Target
$6 -> $3
2025-05-15
downgrade
Buy
Reason
Maxim lowered the firm's price target on Anebulo Pharmaceuticals to $3 from $6 and keeps a Buy rating on the shares after its Q3 results. The company is prioritizing the advancement of IV selonbant into a Phase 1 SAD study in healthy adults, and the firm adjusting its price target to reflect this pivot, though Maxim remains positive on Anebulo given the unmet need in severe cannabis toxicity, the analyst tells investors in a research note.
Benchmark
Robert Wasserman
Buy
Reiterates
$8
2024-11-19
Reason
Benchmark
Robert Wasserman
Price Target
$8
2024-11-19
Reiterates
Buy
Reason
Benchmark
Robert Wasserman
Buy
Reiterates
$8
2024-10-01
Reason
Benchmark
Robert Wasserman
Price Target
$8
2024-10-01
Reiterates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Anebulo Pharmaceuticals Inc (ANEB.O) is -5.21, compared to its 5-year average forward P/E of -7.99. For a more detailed relative valuation and DCF analysis to assess Anebulo Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-7.99
Current PE
-5.21
Overvalued PE
-0.25
Undervalued PE
-15.72
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q3
YoY :
+13.70%
-1.89M
Operating Profit
FY2025Q3
YoY :
+1.37%
-1.68M
Net Income after Tax
FY2025Q3
YoY :
-33.33%
-0.04
EPS - Diluted
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
10.0M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
10.0M
USD
Months
0-12
0
0.0
USD
Months
ANEB News & Events
Events Timeline
2025-02-14 (ET)
2025-02-14
16:06:22
Anebulo Pharmaceuticals reports Q4 EPS (9c) vs. (11c) last year
2024-12-23 (ET)
2024-12-23
08:21:01
Anebulo Pharmaceuticals collaborates with FDA to advance selonabant
2024-09-25 (ET)
2024-09-25
16:07:25
Anebulo Pharmaceuticals reports Q4 EPS (5c) vs. (10c) last year
Sign Up For More Events
Sign Up For More Events
News
4.0
07-23BenzingaMaxim Group Downgrades Anebulo Pharmaceuticals to Hold
4.5
07-23BenzingaCrude Oil Falls; Thermo Fisher Scientific Earnings Top Views
2.0
07-23BenzingaDow Surges Over 200 Points; AT&T Posts Upbeat Earnings
Sign Up For More News
People Also Watch
NXL
Nexalin Technology Inc
0.838
USD
-4.66%
INTZ
Intrusion Inc
1.820
USD
-4.71%
BRFH
Barfresh Food Group Inc
3.050
USD
+0.66%
DXR
Daxor Corp
11.030
USD
-3.08%
KPLT
Katapult Holdings Inc
12.790
USD
+1.43%
TPST
Tempest Therapeutics Inc
9.340
USD
+6.02%
SCNX
Scienture Holdings Inc
2.220
USD
+6.22%
IZEA
IZEA Worldwide Inc
3.620
USD
-6.22%
CMMB
Chemomab Therapeutics Ltd
0.958
USD
+3.57%
FCUV
Focus Universal Inc
2.290
USD
-0.43%
FAQ
What is Anebulo Pharmaceuticals Inc (ANEB) stock price today?
The current price of ANEB is 2.4 USD — it has increased 0.84 % in the last trading day.
What is Anebulo Pharmaceuticals Inc (ANEB)'s business?
What is the price predicton of ANEB Stock?
What is Anebulo Pharmaceuticals Inc (ANEB)'s revenue for the last quarter?
What is Anebulo Pharmaceuticals Inc (ANEB)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Anebulo Pharmaceuticals Inc (ANEB)'s fundamentals?
How many employees does Anebulo Pharmaceuticals Inc (ANEB). have?